216 related articles for article (PubMed ID: 24443277)
1. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.
Struemper H; Sale M; Patel BR; Østergaard M; Österborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
J Clin Pharmacol; 2014 Jul; 54(7):818-27. PubMed ID: 24443277
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Ogura M; Hatake K; Tobinai K; Uchida T; Suzuki T; Terui Y; Yokoyama M; Maruyama D; Mori M; Jewell RC; Katsura K; Hotta T
Jpn J Clin Oncol; 2013 May; 43(5):466-75. PubMed ID: 23456745
[TBL] [Abstract][Full Text] [Related]
3. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
5. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Hagenbeek A; Gadeberg O; Johnson P; Pedersen LM; Walewski J; Hellmann A; Link BK; Robak T; Wojtukiewicz M; Pfreundschuh M; Kneba M; Engert A; Sonneveld P; Flensburg M; Petersen J; Losic N; Radford J
Blood; 2008 Jun; 111(12):5486-95. PubMed ID: 18390837
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study.
Coiffier B; Losic N; Rønn BB; Lepretre S; Pedersen LM; Gadeberg O; Frederiksen H; van Oers MH; Wooldridge J; Kloczko J; Holowiecki J; Hellmann A; Walewski J; Robak T; Petersen J
Br J Haematol; 2010 Jul; 150(1):58-71. PubMed ID: 20408846
[TBL] [Abstract][Full Text] [Related]
7. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
Nightingale G
Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
[TBL] [Abstract][Full Text] [Related]
8. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab.
Zhang B
MAbs; 2009; 1(4):326-31. PubMed ID: 20068404
[TBL] [Abstract][Full Text] [Related]
10. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.
Coiffier B; Lepretre S; Pedersen LM; Gadeberg O; Fredriksen H; van Oers MH; Wooldridge J; Kloczko J; Holowiecki J; Hellmann A; Walewski J; Flensburg M; Petersen J; Robak T
Blood; 2008 Feb; 111(3):1094-100. PubMed ID: 18003886
[TBL] [Abstract][Full Text] [Related]
12. Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion.
Tempescul A; Bagacean C; Riou C; Bendaoud B; Hillion S; Debant M; Buors C; Berthou C; Renaudineau Y
Eur J Haematol; 2016 Mar; 96(3):229-35. PubMed ID: 25911969
[TBL] [Abstract][Full Text] [Related]
13. An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia.
Patton WN; Lindeman R; Butler AC; Kipps TJ; Jewell RC; Laubscher KH; Zhou YY; Lewis E; Sedoti D; Witman P; Fang L; Chan G
Leuk Lymphoma; 2015; 56(10):2819-25. PubMed ID: 25721750
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
Czuczman MS; Fayad L; Delwail V; Cartron G; Jacobsen E; Kuliczkowski K; Link BK; Pinter-Brown L; Radford J; Hellmann A; Gallop-Evans E; DiRienzo CG; Goldstein N; Gupta I; Jewell RC; Lin TS; Lisby S; Schultz M; Russell CA; Hagenbeek A;
Blood; 2012 Apr; 119(16):3698-704. PubMed ID: 22389254
[TBL] [Abstract][Full Text] [Related]
15. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
16. Ofatumumab.
Sanford M; McCormack PL
Drugs; 2010 May; 70(8):1013-9. PubMed ID: 20481657
[TBL] [Abstract][Full Text] [Related]
17. Ofatumumab for the treatment of chronic lymphocytic leukemia.
Grosicki S
Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470
[TBL] [Abstract][Full Text] [Related]
18. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
[TBL] [Abstract][Full Text] [Related]
19. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Future Oncol; 2014 May; 10(7):1147-55. PubMed ID: 24947256
[TBL] [Abstract][Full Text] [Related]
20. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.
Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJ; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Osterborg A;
J Clin Oncol; 2010 Apr; 28(10):1749-55. PubMed ID: 20194866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
